2 ms·
From 2019 re: "post-market" clinical data which is collected after clinical trials and regulatory approval: https://news.ycombinator.com/item?id=21235358 https
by westurner 1y ago
From 2019 re: "post-market" clinical data which is collected after clinical trials and regulatory approval:
https://news.ycombinator.com/item?id=21235358 https://news.ycombinator.com/item?id=21235358 :
> We really could get more out of this data through international collaboration and through linked data (e.g. URIs for columns). See: "Open, and Linked, FDA data" https://github.com/FDA/openfda/issues/5#issuecomment-5392966 https://github.com/FDA/openfda/issues/5#issuecomment-5392966... and "ENH: Adverse Event Count / 'Use' Count Heatmap" https://github.com/FDA/openfda/issues/49 https://github.com/FDA/openfda/issues/49
> With sales/usage counts, we'd have a denominator with which we could calculate relative hazard.
- westurner 1y agoFHIR is a standard for sharing health data. FHIR would be useful for sharing collected clinical data - for example vitals - with patients and their other providers if they choose. FHIR could be useful for collecting chart data from clinical trial participants. FHIR can be represented in JSON-LD, which is Linked Data in JSON such that no XML parsing is required. Re: FHIR JSON-LD https://news.ycombinator.com/item?id=42230270 https://news.ycombinator.com/item?id=42230270 : > /? awesome clinical open source: https://www.google.com/search?q=awesome+clinical+open+source https://www.google.com/search?q=awesome+clinical+open+source